Granules India Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Small Cap

Granules India informed that its unit V facility located at Anakapally, Visakhapatnam, Andhra Pradesh, India underwent a United States Food and Drug Administration (USFDA) inspection from 8 April 2024 to 12th April 2024.

This audit was a pre-approval inspection (PAI) and current good manufacturing practice (cGMP) audit for active pharmaceutical ingredients (APIs) and formulations (FDs); oncology and non-oncology.

This facility manufactures APIs & formulations of oncology and non-oncology products.

Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs).

The pharma company's consolidated net profit rose 1.06% to Rs 125.65 crore on 0.82% increase in revenue from operations to Rs 1,155.58 crore in Q3 FY24 over Q3 FY23.

The scrip declined 1.14% to settle at Rs 421.95 on Friday, 12 April 2024.

Powered by Capital Market - Live News

The drug maker has announced that it has received a communication from the United States Food and Drug Administration (USFDA) indicating the inspection classification as ‘Voluntary Action Indicated’ (VAI). The inspection was conducted at company’s wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), located in Chantilly, Virginia, USA.

The USFDA had issued Form 483 with 5 observations post inspection on 16 December 2023, which has been now classified as VAI.

This classification indicates that the US drug regulator will not take or recommend regulatory or enforcement action because the observations do not meet the threshold for action at this time.

Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs).

The pharma company's consolidated net profit rose 1.06% to Rs 125.65 crore on 0.82% increase in revenue from operations to Rs 1,155.58 crore in Q3 FY24 over Q3 FY23.

The scrip rose 0.90% to currently trade at Rs 449 on the BSE.

Powered by Capital Market - Live News

Granules India Ltd is up for a third straight session today. The stock is quoting at Rs 445, up 1.61% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.18% on the day, quoting at 22422.6. The Sensex is at 73834.89, down 0.24%. Granules India Ltd has slipped around 4.71% in last one month.

Meanwhile, Nifty Pharma index of which Granules India Ltd is a constituent, has slipped around 1.02% in last one month and is currently quoting at 19207.9, down 0.28% on the day. The volume in the stock stood at 4.7 lakh shares today, compared to the daily average of 8.18 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 446.55, up 1.28% on the day. Granules India Ltd is up 49.66% in last one year as compared to a 28.88% jump in NIFTY and a 58.71% jump in the Nifty Pharma index.

The PE of the stock is 22.46 based on TTM earnings ending December 23.

Powered by Capital Market - Live News

Granules India Ltd dropped for a fifth straight session today. The stock is quoting at Rs 417.4, down 2.67% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 1.08% on the day, quoting at 22093.65. The Sensex is at 72980.39, down 0.93%.Granules India Ltd has lost around 3.35% in last one month.Meanwhile, Nifty Pharma index of which Granules India Ltd is a constituent, has increased around 0.4% in last one month and is currently quoting at 18958.7, down 1.58% on the day. The volume in the stock stood at 8.78 lakh shares today, compared to the daily average of 17.56 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 419.3, down 2.68% on the day. Granules India Ltd jumped 47.1% in last one year as compared to a 29.63% rally in NIFTY and a 60.88% spurt in the Nifty Pharma index.

The PE of the stock is 22.4 based on TTM earnings ending December 23.

Powered by Capital Market - Live News